- Home
- MDAI vs RNXT Comparison
MDAI vs RNXT Comparison
Compare MDAI & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDAI | RNXT |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 37.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDAI | RNXT |
|---|---|---|
| Price | $2.08 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 893.9K | 279.4K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | $23.50 | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $1.18 | $0.70 |
| 52 Week High | $3.21 | $1.45 |
Technical Indicators
Market Signals| Indicator | MDAI | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 52.86 |
| Support Level | $1.85 | $0.80 |
| Resistance Level | $2.80 | $1.07 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 23.48 | 66.86 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.